What Teva Pharmaceuticals does

Teva Pharmaceutical Industries Ltd. is a publicly traded global pharmaceutical company (NYSE/TASE: TEVA) headquartered in Tel Aviv, Israel, with U.S. operations centered in Parsippany, New Jersey. Founded over 120 years ago, the company operates in approximately 60 countries, manufactures and distributes more than 3,500 pharmaceutical products, and reaches approximately 200 million patients daily. It operates three core commercial streams: (1) the world's leading generics business, (2) an innovative/specialty branded portfolio anchored by AUSTEDO/AUSTEDO XR (deutetrabenazine, VMAT2 inhibitor), AJOVY (fremanezumab anti-CGRP for migraine), and UZEDY (long-acting injectable risperidone for schizophrenia), and (3) a biosimilars platform with 11 products on market and 13 in pipeline, including AHZANTIVE (aflibercept biosimilar to Eylea) launched in Europe in 2026.

Teva's revenue model is built on direct sale of generic and specialty medicines through pharmacy, hospital, specialty pharmacy, and wholesale distribution channels globally, supplemented by licensing/royalty arrangements such as the $400M Blackstone Life Sciences funding agreement for duvakitug (anti-TL1A antibody in Phase 3 for ulcerative colitis and Crohn's disease) and milestone/royalty payments from partners including Sanofi (co-development) and Medincell (SteadyTeq/BEPO long-acting injectable technology). The go-to-market combines enterprise field sales for specialty brands, payer negotiations and formulary positioning, and channel partnerships for biosimilar commercialization in Europe (Klinge Biopharma, Formycon AG). Q1 2026 sales reached $3.98 billion, and full-year 2026 guidance was raised to $16.4-$16.8 billion, with EPS guidance of $1.91-$2.11.

Under its Pivot to Growth strategy announced in May 2023, Teva is shifting its mix from generics toward innovative branded medicines and biosimilars. The innovative portfolio generated $709 million in U.S. sales in Q1 2026, surpassing U.S. generics for the first time, with AUSTEDO growing 41% and UZEDY growing 62% year-over-year. The late-stage pipeline includes ecopipam (acquired via the $700M Emalex Biosciences deal closed in June 2026, NDA submitted for pediatric Tourette syndrome), TEV-'749 olanzapine long-acting injectable (MAA accepted by EMA in May 2026), duvakitug (Phase 3 anti-TL1A), and emrusolmin (FDA Fast Track for Multiple System Atrophy). Fitch upgraded Teva to Investment Grade BBB- in May 2026, the third such upgrade in under two years.

Name

Teva Pharmaceuticals

Legal name

Teva Pharmaceutical Industries Ltd.

Website

https://tevausa.com

Company type

Public

Founded year

1901

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Teva Pharmaceutical Industries Ltd. is a publicly traded global pharmaceutical company (NYSE/TASE: TEVA) that develops, manufactures, and distributes generic, specialty branded, and biosimilar medicines to approximately 200 million patients across 60+ countries. Its innovative portfolio (AUSTEDO, AJOVY, UZEDY) and biosimilars franchise are increasingly offsetting mature generics under its Pivot to Growth strategy.

Ownership category

akta.pro rank

Product category

Generic and Specialty Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)

akta.pro secondary industry

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)

Keywords

• Generic pharmaceuticals
• Specialty branded medicines
• Biosimilar development
• Neuroscience treatments
• Long-acting injectables

Headquarters

HQ city

North Wales

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Marketing or Sales, Operations, Personnel, Infrastructure

Revenue model

1. Generic Pharmaceuticals: World's leading manufacturer of generic medicines. Revenue from generic drug sales across multiple therapeutic areas distributed through pharmacies and hospitals globally.
2. Innovative/Specialty Branded Medicines: Branded medicines including AUSTEDO, AJOVY, UZEDY for neuroscience and immunology. Q1 innovative portfolio generated $709 million in U.S. sales, surpassing U.S. generics for first time.
3. Biosimilars: Commercialization of biosimilar medicines including AHZANTIVE (aflibercept) in Europe. Revenue from biosimilar sales through partnerships and direct distribution.
4. Partnership Milestones and Royalties: Blackstone Life Sciences provides $400M funding for duvakitug development in exchange for regulatory/commercial milestones and low single-digit royalties on worldwide sales.
5. Acquisition Payments: Ecopipam acquisition from Emalex Biosciences for $700M upfront plus up to $200M in commercial milestones and royalties upon successful commercialization.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Teva is a global biopharmaceutical company that develops, manufactures, and commercializes more than 3,500 generic medicines alongside branded specialty/innovative drugs and biosimilars across neuroscience, immunology, migraine, oncology, ophthalmology, and respiratory care. Its branded franchises include AUSTEDO/AUSTEDO XR for tardive dyskinesia and Huntington's disease chorea, AJOVY for migraine prevention, UZEDY for schizophrenia, AHZANTIVE as an Eylea biosimilar, and pipeline assets such as ecopipam for pediatric Tourette syndrome and duvakitug for inflammatory bowel disease.

Differentiator

Problem solved

Functional benefit

Brands

• AUSTEDO (deutetrabenazine): VMAT2 inhibitor for treatment of chorea associated with Huntington's disease and tardive dyskinesia
• AUSTEDO XR
• AJOVY
• UZEDY
• AHZANTIVE (aflibercept)
• TEV-'749 (olanzapine LAI)
• Ecopipam
• Copaxone

Products and services

• AUSTEDO (deutetrabenazine)

Quantifiable outcome

• Q1 2026 sales of $3.98 billion exceeded FactSet projections by $100 million
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• MedincellcoreStrategic or Co-development Partner · 21 May 2026Co-development of olanzapine long-acting injectable (TEV-'749) using Medincell's SteadyTeq copolymer technology. EMA accepted MAA in May 2026. Medincell receives royalties on sales; first treatment based on BEPO technology was approved by FDA in April 2023 and is distributed by Teva as UZEDY.
• H. LundbeckminorOthers · 21 April 2026Lundbeck identified as key company in Multiple System Atrophy pipeline with 22+ therapies in development. Teva received FDA Fast Track designation for emrusolmin in MSA. Both companies competing in rare neurodegenerative space.
• Direct ReliefminorGTM or Marketing Partner · 14 April 2026Second round of grant funding collaboration providing $75,000 each to 11 free and charitable clinics across Alabama, Mississippi, and Texas. Teva committed $2 million over two years to Community Routes program which has reached over 120,000 beneficiaries since 2022.
• Schneider ElectricminorOthers · 23 September 2025Schneider Electric advised Teva on a 15-year Virtual Power Purchase Agreement (VPPA) with renewable energy provider Enery for a new solar project in Bulgaria. Project delivers approximately 200 GWh renewable energy annually and helps Teva avoid 15,840 metric tons CO2e emissions per year.
• Klinge Biopharma GmbHcoreChannel Partner/ Reseller/ Distributor · 1 May 2025Semi-exclusive commercialization agreement for AHZANTIVE (aflibercept biosimilar to Eylea) in major parts of Europe and Israel. Launch began May 2026 across France, Germany, Spain, and The Netherlands.
• Formycon AGcoreChannel Partner/ Reseller/ Distributor · 1 May 2025Semi-exclusive commercialization agreement for AHZANTIVE (aflibercept biosimilar to Eylea) in major parts of Europe and Israel. Partnership for biosimilar commercialization in ophthalmology.
• SanoficoreStrategic or Co-development Partner · 1 January 2023Co-development and co-commercialization agreement for duvakitug, subject to regulatory approval. Sanofi and Teva collaborating on this immunology asset targeting TL1A for inflammatory bowel disease.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Apotex: Canadian-based generics manufacturer with strong North American presence, competing with Teva in U.S. and Canadian generic distribution and select specialty categories.
• Lundbeck: Danish CNS-focused pharmaceutical company. Both compete in migraine (Vyepti vs. AJOVY) and rare neurological diseases. Both identified as key players in the Multiple System Atrophy pipeline.
• Dr. Reddy's Laboratories: Indian multinational with global generics footprint and biosimilars pipeline. Direct competitor in U.S. and emerging market generics, with growing specialty and biosimilar segments.
• Viatris: Formed via Mylan-Upjohn merger, Viatris is a global generics and specialty pharmaceutical major with overlapping therapeutic breadth (CNS, immunology) and similar biosimilars ambitions. Direct head-to-head with Teva in generic distribution and select specialty categories.
• Neurocrine Biosciences: Neuroscience-focused biotech whose Ingrezza (valbenazine) is the most direct competitor to AUSTEDO in tardive dyskinesia. Highly comparable specialty CNS commercial model targeting movement disorder specialists.
• Sun Pharmaceutical Industries: India-based global generics leader with specialty branded presence. Competes directly with Teva in generic APIs and finished dosage, and increasingly in specialty dermatology and CNS.
• Sandoz: Novartis's generics and biosimilars spinoff is Teva's closest direct competitor globally, with comparable generics breadth and a growing biosimilars portfolio (hyrimoz, epoetin, etc.). Both companies target interchangeable biosimilars markets and compete for global pharmacy contracts.
• Lupin Pharmaceuticals: India-headquartered global generic pharma with growing complex generics and biosimilars. Direct competitor in U.S. generics market and select emerging market regions.

Broad incumbents

• Amgen: Major biologics manufacturer with biosimilars (Amjevita, Kanjinti, Mvasi) competing directly with Teva's biosimilars. Broader pipeline and oncology/inflammation footprint make Amgen an incumbent competitor.

Emerging players

• Samsung Bioepis: Samsung's biosimilars-focused JV with Biogen competes directly with Teva in oncology, immunology, and ophthalmology biosimilars. Pure-play biosimilars model with growing global commercial reach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/TevaUSA
• YouTubeyoutube.com/c/tevapharm
• Facebookfacebook.com/TevaUSA
• LinkedInlinkedin.com/company/teva-pharmaceuticals-usa-inc.

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Teva Pharmaceuticals